Article
Medicine, General & Internal
Mallika Marar, Qi Long, Ronac Mamtani, Vivek Narayan, Neha Vapiwala, Ravi B. Parikh
Summary: This study investigated the differences in outcomes between African American and non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC) who received first-line abiraterone therapy. The results showed that African American men had a higher overall survival when receiving first-line abiraterone compared to non-Hispanic White men. However, there was a difference in outcomes between the two groups for first-line enzalutamide treatment.
Review
Nutrition & Dietetics
Rebekah L. Wilson, Dennis R. Taaffe, Robert U. Newton, Nicolas H. Hart, Philippa Lyons-Wall, Daniel A. Galvao
Summary: Fat mass gain and lean mass loss are common side effects for prostate cancer patients receiving androgen deprivation therapy. Implementing a combined exercise and nutrition program could potentially reduce or even reverse these effects and improve disease progression and quality of life for patients. The most effective combination of specific exercise and nutrition prescriptions for these patients still needs to be determined.
Article
Oncology
Hugh Elbourne, Wee Kheng Soo, Victoria O'Reilly, Anna Moran, Christopher B. Steer
Summary: Despite a third of patient respondents indicating an interest in a supervised exercise program, only 16% of patients with prostate cancer undergoing ADT at a regional cancer centre engaged in a discussion about exercise with their treating clinicians. Physical limitations and fatigue were the greatest barriers for patients. Clinicians indicated a need for more clinician education and better integration of exercise specialists into clinical care.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Medicine, General & Internal
Shabbir M. H. Alibhai, Henriette Breunis, Gregory Feng, Narhari Timilshina, Aaron Hansen, Padraig Warde, Richard Gregg, Anthony Joshua, Neil Fleshner, George Tomlinson, Urban Emmenegger
Summary: This study longitudinally examined cognitive function in older men with metastatic castration-resistant prostate cancer undergoing treatment with docetaxel, abiraterone, enzalutamide, and radium Ra 223. The findings suggest that most older men do not experience significant cognitive decline in attention, executive function, and global cognition regardless of the treatment used.
Article
Oncology
Dandan Song, Yingying Hu, Biyu Diao, Rongrong Miao, Baodan Zhang, Yangjun Cai, Hanqian Zeng, Yuru Zhang, Xiaoqu Hu
Summary: The study found that compared to TOR, TAM increased the risk of new-onset and severe fatty liver, while TOR helped improve lipid profiles and reduce the risk of liver fibrosis, suggesting the need for continuous monitoring of liver imaging and serum lipid levels during SERM treatment.
Article
Medicine, General & Internal
Barbara Bressi, Cinzia Iotti, Maribel Cagliari, Silvio Cavuto, Stefania Fugazzaro, Stefania Costi
Summary: This study aims to investigate the feasibility and safety of a multicomponent physical exercise intervention for prostate cancer patients. It will examine the effects of exercise on quality of life, physical and cognitive functions, and evaluate its safety and adherence. The results of this study can provide better treatment options for individuals with prostate cancer.
Article
Oncology
Sagar A. Patel, Ting Martin Ma, Jessica K. Wong, Bradley J. Stish, Robert T. Dess, Avinash Pilar, Chandana Reddy, Trude B. Wedde, Wolfgang A. Lilleby, Ryan Fiano, Gregory S. Merrick, Richard G. Stock, D. Jeffrey Demanes, Brian J. Moran, Phuoc T. Tran, Daniel J. Krauss, Eyad I. Abu-Isa, Thomas M. Pisansky, C. Richard Choo, Daniel Y. Song, Stephen Greco, Curtiland Deville, Theodore L. DeWeese, Derya Tilki, Jay P. Ciezki, R. Jeffrey Karnes, Nicholas G. Nickols, Matthew B. Rettig, Felix Y. Feng, Alejandro Berlin, Jonathan D. Tward, Brian J. Davis, Robert E. Reiter, Paul C. Boutros, Tahmineh Romero, Eric M. Horwitz, Rahul D. Tendulkar, Michael L. Steinberg, Daniel E. Spratt, Michael Xiang, Amar U. Kishan
Summary: For very-high-risk prostate cancer patients, the addition of brachytherapy to external beam radiation therapy with androgen deprivation therapy did not significantly improve outcomes compared to radiation therapy alone.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Biochemical Research Methods
Zhong Chen, You Lu, Bo Cao, Wensheng Zhang, Andrea Edwards, Kun Zhang
Summary: This study aimed to integrate multi-dimensional genomic data to identify cancer-related driver genes and estimate disease propagation at the patient and/or cohort levels. The proposed method was validated and shown to effectively address tumor heterogeneity in personalized medicine.
Review
Oncology
Matthew Alberto, Arthur Yim, Nathan Lawrentschuk, Damien Bolton
Summary: Advanced prostate cancer has a higher mortality rate compared to localized prostate cancer, making it crucial to study its development mechanisms and potential pathways for novel treatments. Prostate cancer is the second most common cancer in men, with increasing prevalence due to an aging population. It is important to understand the evolving mechanisms of progression in order to address the significant morbidity and mortality associated with advanced prostate cancer, where treatment options are linked to lipid metabolism.
Article
Oncology
Jane C. Figueiredo, Gillian Gresham, Elizabeth L. Barry, Leila A. Mott, Michael N. Passarelli, Patrick T. Bradshaw, Carlton W. Anderson, John A. Baron
Summary: This study investigated the relationship between sex hormone levels and risk of colorectal precursors in 925 men. The findings fill the gap in the research on sex hormones in men.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Derya Tilki, Ming-Hui Chen, Jing Wu, Hartwig Huland, Markus Graefen, Thomas Wiegel, Dirk Boehmer, Osama Mohamad, Janet E. Cowan, Felix Y. Feng, Peter R. Carroll, Bruce J. Trock, Alan W. Partin, Anthony D'Amico
Summary: The study found that adjuvant radiation therapy compared to early salvage radiation therapy significantly reduces all-cause mortality in men with adverse pathology, such as positive pelvic lymph nodes or high Gleason score prostate cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Ada S. Cheung, Rudolf Hoermann, Jasmine Zhu, Daryl Lim Joon, Jeffrey D. Zajac, Mathis Grossmann
Summary: The study aimed to investigate the effects of zoledronic acid on fat mass and glucose metabolism in men undergoing ADT, with results showing no exacerbation of ADT-induced insulin resistance by zoledronic acid. Both groups experienced an increase in fat mass and a decrease in lean mass, but there was no significant difference between the two groups.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
(2021)
Review
Oncology
Kellie Toohey, Maddison Hunter, Catherine Paterson, Reza Mortazavi, Benjamin Singh
Summary: Androgen deprivation therapy (ADT) for prostate cancer treatment is associated with adverse physiological changes; however, exercise can improve outcomes. This systematic review and meta-analysis aimed to determine exercise intervention adherence and its effects on physiological outcomes in men diagnosed with prostate cancer undergoing ADT. Uniquely, this review incorporated a meta-aggregation of qualitative data, providing perspectives from the men's experiences.
Article
Medicine, General & Internal
E. Lin, Hans Garmo, Mieke Van Hemelrijck, Bjorn Zethelius, Par Stattin, Emil Hagstrom, Jan Adolfsson, Danielle Crawley
Summary: This study aimed to evaluate the association between GnRH agonist use, PCa diagnosis, and CVD risk in men with type 2 diabetes. The results showed that men with type 2 diabetes who received GnRH agonist for PCa had an increased risk of CVD and lower blood pressure levels.
Article
Biochemistry & Molecular Biology
Shu-Pin Huang, Yei-Tsung Chen, Lih-Chyang Chen, Cheng-Hsueh Lee, Chao-Yuan Huang, Chia-Cheng Yu, Victor C. Lin, Te-Ling Lu, Bo-Ying Bao
Summary: This study revealed that genetic variants of NRG1 gene are significantly associated with worsening cancer-specific survival, overall survival, and progression-free survival in prostate cancer patients undergoing androgen-deprivation therapy. Low expression of NRG1 is closely related to prostate cancer progression, as indicated by a high Gleason score and shorter progression-free survival rate.